Cellix Bio

Bio-Pharmaceutical

Cellix Bio is a biopharmaceutical company that specializes in drug discovery and development. The company stands out for its use of an AI platform named Synergix, which aids in drug design, focusing on creating new molecular entities that demonstrate synergistic pharmacology. This innovative approach is pivotal in Cellix Bio's mission to develop therapies for a wide range of diseases, including oncological, neurological, inflammatory, metabolic, and others. Cellix Bio's mission is strongly aligned with its technological innovation. It works closely with the scientific community, universities, and research institutions to advance and build the value of its Synergix AI™ technology. The company is dedicated to developing promising intellectual property and creating value for stakeholders and investors. A key aspect of Cellix Bio's approach is its emphasis on addressing unmet medical needs across various therapeutic areas such as neurology, ophthalmology, dermatology, oncology, inflammation, and metabolic diseases. As a subsidiary of Cellix Bio, Cellix Bio Pharma plays a significant role in the parent company's mission. It is a global contract research organization (CRO) focusing on the development of pharmaceutical formulations. Cellix Bio Pharma's expertise in drug discovery, development, and delivery technologies, combined with a strong product development and regulatory filings pipeline in various stages of development, complements the overarching goals of Cellix Bio. The acquisition of Avaca Pharma further strengthens Cellix Bio Pharma's capabilities in pharmaceutical development.